DPP-4 Inhibitors: How They Work for Diabetes and What Else They Might Treat
DPP-4 inhibitors (gliptins) protect incretin hormones from breakdown to control blood sugar, but they may also have therapeutic potential beyond diabetes.
Quick Facts
What This Study Found
DPP-4 is a widely expressed enzyme that clips dipeptides from the N-terminus of peptides containing proline or alanine at position 2. Its most clinically relevant targets are the incretin hormones GLP-1 and GIP, which regulate blood glucose. Several families of DPP-4 inhibitors have been developed, and multiple gliptins are now approved for type 2 diabetes based on their ability to preserve incretin activity and improve glycemic control.
Beyond diabetes, this review highlights that DPP-4 has many other peptide substrates involved in immune regulation, inflammation, and cell signaling — suggesting gliptins could potentially be repurposed for other therapeutic areas.
Key Numbers
How They Did This
This is a Perspective article published in the Journal of Medicinal Chemistry. It reviews the biological functions of DPP-4, the structure-activity relationships of various DPP-4 inhibitor families, their clinical development for type 2 diabetes, and emerging evidence for non-diabetic applications. It synthesizes data from preclinical models and clinical trials.
Why This Research Matters
DPP-4 inhibitors were one of the first peptide-based therapeutic strategies to achieve widespread clinical use in diabetes. Understanding how these drugs protect incretins from enzymatic degradation provides a foundation for understanding the newer GLP-1 receptor agonists (like semaglutide and tirzepatide) that took a different approach to the same problem. The review also flags the broader biological significance of DPP-4, which remains relevant as researchers explore incretin biology beyond blood sugar control.
The Bigger Picture
DPP-4 inhibitors represent an important chapter in incretin-based medicine. While GLP-1 receptor agonists have since overtaken gliptins in terms of efficacy for both diabetes and obesity, understanding DPP-4's role in peptide metabolism remains foundational. This review connects the enzyme's broad substrate specificity to potential therapeutic applications in immunology, oncology, and inflammation — areas still being explored over a decade later.
What This Study Doesn't Tell Us
As a review/perspective article, this does not present new experimental data. The discussion of non-diabetic applications is largely based on preclinical evidence and mechanistic reasoning rather than clinical trials. The field has advanced considerably since 2014, and some predictions about future applications may not have panned out.
Questions This Raises
- ?Have any non-diabetic applications of DPP-4 inhibitors been clinically validated since this review was published?
- ?How does the broad substrate specificity of DPP-4 affect the long-term safety profile of gliptins?
- ?Why did GLP-1 receptor agonists ultimately prove more effective than DPP-4 inhibitors for both diabetes and weight loss?
Trust & Context
- Key Stat:
- Multiple approved gliptins Several DPP-4 inhibitors are approved for type 2 diabetes, with others in clinical evaluation for additional indications
- Evidence Grade:
- This is a review/perspective article that synthesizes existing literature rather than presenting original clinical data. While published in a high-impact journal and authored by an expert, it provides indirect evidence through aggregation of other studies' findings.
- Study Age:
- Published in 2014, this review predates the obesity drug revolution driven by semaglutide and tirzepatide. The core DPP-4 biology remains accurate, but the therapeutic landscape has shifted significantly since publication.
- Original Title:
- Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
- Published In:
- Journal of medicinal chemistry, 57(6), 2197-212 (2014)
- Authors:
- Juillerat-Jeanneret, Lucienne
- Database ID:
- RPEP-02413
Evidence Hierarchy
Frequently Asked Questions
What is DPP-4 and why does blocking it help with diabetes?
DPP-4 is an enzyme that rapidly breaks down incretin hormones like GLP-1 and GIP — the peptides your gut releases after eating to stimulate insulin and lower blood sugar. By blocking DPP-4, gliptin drugs allow these natural hormones to work longer, improving blood sugar control without directly injecting insulin or synthetic hormones.
How are DPP-4 inhibitors different from GLP-1 drugs like semaglutide?
DPP-4 inhibitors protect your body's own GLP-1 from being broken down, modestly boosting its levels. GLP-1 receptor agonists like semaglutide are synthetic versions of GLP-1 that activate the same receptor at much higher levels. That's why GLP-1 agonists tend to produce stronger effects on blood sugar and weight loss, but DPP-4 inhibitors have the advantage of being oral pills with fewer gastrointestinal side effects.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02413APA
Juillerat-Jeanneret, Lucienne. (2014). Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?. Journal of medicinal chemistry, 57(6), 2197-212. https://doi.org/10.1021/jm400658e
MLA
Juillerat-Jeanneret, Lucienne. "Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?." Journal of medicinal chemistry, 2014. https://doi.org/10.1021/jm400658e
RethinkPeptides
RethinkPeptides Research Database. "Dipeptidyl peptidase IV and its inhibitors: therapeutics for..." RPEP-02413. Retrieved from https://rethinkpeptides.com/research/juillerat-jeanneret-2014-dipeptidyl-peptidase-iv-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.